The US dollar is gaining ground as President Biden may eventually pass a large stimulus bill and yields are rising. Meanwhile, America's vaccination campaign is catching up with Britain's, also supporting the greenback and weighing on GBP/USD, FXStreet’s Analyst Yohay Elam reports.
“The US dollar has been gaining ground as investors sell Treasuries in response to higher prospects of a generous relief package. Senate Democrats have advanced a partisan reconciliation bill, taking the first step in potentially approving President Joe Biden's proposed $1.9 trillion stimulus package. The unilateral move by Biden's party raises the chances for ‘going big’ – support worth closer to the upper edge.”
“America's economy is getting a shot in the arm from a ramped-up vaccination campaign. Pharmacies are set to begin administering vaccines next week while both Pfizer and Moderna also upgraded its forecast for delivering doses of the vaccine.”
“Support awaits at the weekly low of 1.3610, followed by 1.3520 and 1.3455, which were stepping stones on the way up in January. Resistance is at 1.675, the recent high, followed by 1.3720, a previous 2021 peak, and then by 1.3752, the multi-year high.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.